Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005797 · ClinicalTrials.gov registry record · Phase 1
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01005797 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 38 participants.
The verdict
NCT01005797, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.
Interventions
- DRUG Panobinostat (LBH589), Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-11 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005797
The ClinicalTrials.gov registry entry for NCT01005797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panobinostat (LBH589), Sorafenib is the first listed.
NCT01005797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005797 about?
NCT01005797 is a clinical study titled "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers". The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.
What is the current status of trial NCT01005797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2009-11. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01005797?
The interventions under investigation include: Panobinostat (LBH589), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01005797?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.